Shaily Engineering Plastics Limited — Investor Meet, 17-08-2026: Analysts/Institutional Investor Meet/Con. Call Updates

Shaily Engineering Plastics' Q1 FY27 saw revenue rise 14% to ₹281 Cr, EBITDA 18% to ₹83 Cr (29.7% margin), and PAT 17% to ₹48 Cr (17.1% margin). Healthcare revenue surged 85% to ₹142 Cr, now 51% of total, driven by pen injectors. The company will increase pen injector capacity to 75 million annually by September. Management is confident in exceeding the 36 million annual pen guidance. Strategic focus includes scaling GLP-1/insulin, developing emergency use, reusable, and on-body injectors, and pursuing innovator partnerships. Consumer Electronics aims for $10 million revenue in 24-30 months. Sentiment is confident on future growth.